Search clinical trials for: TOL-3021

Total 9994 results

Tolerion, Inc.

Active, not recruiting

Diabetes Autoimmunity Withdrawn In New Onset and In Established Patients (SUNRISE)

Diabetes Mellitus, Type 1

United States
Tolerion, Inc.

Withdrawn

Diabetes Autoimmunity Withdrawn in New Onset Patients (DAWN) (DAWN)

Diabetes Mellitus, Type 1

United States
Tolerion, Inc.

Withdrawn

Diabetes AutoimmunitY Withdrawn in Established Patients (DAY) (DAY)

Diabetes Mellitus, Type 1
Ospedale San Raffaele

Unknown

Mavrilimumab in Severe COVID-19 Pneumonia and Hyper-inflammation (COMBAT-19) (COMBAT-19)

Covid-19 | Acute Respiratory Failure | ARDS, Human | Sars-CoV2 | Viral Pneumonia

Italy
Hookipa Biotech GmbH

Recruiting

HB-302/HB-301 Therapy in Participants With Metastatic Castration-Resistant Prostate Cancer

Prostate Cancer Metastatic

United States
Swiss Tropical & Public Health Institute
Pevion Biotech Ltd; Mymetics Corporation

Completed

Phase Ib Trial of Two Virosome Formulated Malaria Vaccine Components (PEV 301, PEV 302) in Tanzania (PMAL03)

Falciparum Malaria

Tanzania
Elevation Oncology

Recruiting

Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2

Neoplasms | Neoplasms by Site | Gastrointestinal Neoplasms | Digestive System Neoplasm | Pancreas Neoplasm | Stomach Neoplasm

United States, Japan
BioLineRx, Ltd.

Terminated

A Study Intended to Evaluate Safety, Tolerability and Pharmacokinetics (PK) Parameters of BL-1021

Healthy | Volunteers

Israel
Zhuhai Yufan Biotechnologies Co., Ltd

Recruiting

A Phase I/II Study to Evaluate the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors

Advanced Solid Tumor | Advanced Solid Malignancies

China
Zhuhai Yufan Biotechnologies Co., Ltd

Recruiting

A Phase I Study, Evaluating the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors

Advanced Solid Tumor | Advanced Solid Malignancies

United States
Novo Nordisk A/S

Terminated

A Multi-centre, Open Labelled, Multiple Dosing Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC 0172-2021 Administered Subcutaneously to Healthy Male Subjects and Haemophilia Subjects (explorer™2)

Healthy | Congenital Bleeding Disorder | Haemophilia A

Austria, Spain, United Kingdom, France, Germany
Cryonove Pharma
CEISO; Dermatech; LTD HEALTH

Completed

Tolerance and Performance (Mode of Administration) of Cyto-selective Difluoroethane-based Cryotherapy in the Treatment of Brown Spots

Lentigo Solar | Senile Lentigo

Georgia
Xuanzhu Biopharmaceutical Co., Ltd.

Not yet recruiting

A Study of XZP-3621 in Chinese Patients With ALK Positive NSCLC

ALK-positive NSCLC

China
Xuanzhu Biopharmaceutical Co., Ltd.

Not yet recruiting

Food Effect and Mass Balance Study of XZP-3621 Tablets

Healthy

China
European Organisation for Research and Treatment...

Completed

ISIS 3521 in Treating Patients With Advanced, Unresectable, or Metastatic Non-small Cell Lung Cancer or Unresectable or Metastatic Melanoma

Lung Cancer | Melanoma (Skin)

France, Netherlands, Norway, Belgium, Switzerland, United Kingdom, Germany, Denmark, Austria
Advanced BioDesign

Active, not recruiting

First-in-human Study Aiming to Characterize the Safety, Tolerability, Pharmacokinetic and Preliminary Signs of Activity of ABD-3001 in Refractory or Relapsed AML and High Risk MDS Adult Patients (ODYSSEY)

Myelodysplastic Syndromes | Acute Myeloid Leukemia, Adult

France
French Society for Intensive Care

Completed

Evaluation of the Sanitary Safety of a Healthcare Professional Conference Held 9-11 June 2021 in Paris (COVID-FREE)

Covid19

France
Sumitomo Pharma Co., Ltd.

Completed

DSP-3025 A Phase 1 Study of Healthy Male Volunteers

Healthy

Japan
Sumitomo Pharma Co., Ltd.

Completed

DSP-3025 Study of Healthy Male Volunteers and Seasonal Allergic Rhinitis Male Patients Out of Season

Allergic Rhinitis | Healthy Volunteer

Japan
Novo Nordisk A/S

Completed

Investigation of the Pharmacokinetics of NNC172-2021, at Two Different Dose Levels, in Healthy Japanese Subjects

Healthy | Congenital Bleeding Disorder | Haemophilia A | Haemophilia B

United Kingdom
Xuanzhu Biopharmaceutical Co., Ltd.

Recruiting

A Phase I Study of XZP-3621 in Chinese Patients With ALK or ROS1 Rearrangement Non-small Cell Lung Cancer

ROS1 Rearrangement Non-small Cell Lung Cancer | ALK Rearrangement Non-small Cell Lung Cancer

China
Dolorgiet GmbH & Co. KG
d.s.h. statistical services GmbH; CenTrial GmbH

Completed

Study Whose Purpose is to Find an Optimal Dose for the Treatment With AK 3012 in Patients With Actinic Keratosis

Actinic Keratosis Olsen Grade I/II

Germany
Arcturus Therapeutics, Inc.

Completed

Ascending Dose Study of Investigational SARS-CoV-2 Vaccine ARCT-021 in Healthy Adult Subjects

SARS-CoV-2

Singapore
M. Arkin 1999 Ltd.
Vyne Therapeutics Inc.

Completed

Clinical Study to Evaluate Tolerability and Safety of ARK-E021 Foam and to Monitor Clinical Effect in Acne Vulgaris Patients

Acne Vulgaris

Israel
Shenzhen Xbiome Biotech Co., Ltd.
Beijing Improve-Quality Tech.Co., Ltd.

Recruiting

Safety and Tolerability of FMT Capsules in Healthy Volunteers

Acute-graft-versus-host Disease

China
Mitsubishi Tanabe Pharma America Inc.

Completed

Safety and Pharmacokinetics Study of MT-3921 in Spinal Cord Injury

Spinal Cord Injury

United States
Alaunos Therapeutics

Completed

Trial of an Intratumoral Injections of INXN-3001 in Subjects With Stage III or IV Melanoma

Melanoma

United States
Flame Biosciences

Withdrawn

Phase 1/2a Study to Evaluate FL-301 in Patients With Advanced Solid Tumors

Gastric Cancer | Solid Tumor | Pancreas Cancer
Dong-A ST Co., Ltd.

Completed

A Study to Evaluate Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Tripegfilgrastim in Pediatric Solid Tumor/Lymphoma Patients

Lymphoma | Solid Tumor

Korea, Republic of
Sensei Biotherapeutics, Inc.
Accelovance

Completed

Phase 1 Trial of PAN-301-1 (SNS-301) in Cancer Patients

Prostate Cancer

United States
Lumen Bioscience, Inc.

Recruiting

A Study to Determine the Tolerability of Intranasal LMN-301

COVID-19

Australia
University of Alabama at Birmingham

Recruiting

NTX-301 in MDS/AML

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myelomonocytic Leukemia

United States
Kodiak Sciences Inc

Terminated

Exploratory Study to Investigate the Bioactivity, Ocular and Systemic Safety, Tolerability, and Pharmacokinetics Following Single and Multiple Intravitreal Administrations of KSI-301 in Subjects With wAMD, DME and RVO

Diabetic Macular Edema | Retinal Vein Occlusion | Wet Age-related Macular Degeneration

United States
Rubius Therapeutics

Terminated

RTX-321 Monotherapy in Patients With HPV 16+ Tumors

Cervical Cancer | Head and Neck Cancer | Anal Cancer

United States
Oncolys BioPharma Inc
Medigen Biotechnology Corporation

Unknown

Phase I Study to Evaluate the Safety and Efficacy of Telomelysin (OBP-301) in Patients With Hepatocellular Carcinoma

Carcinoma, Hepatocellular

Taiwan, Korea, Republic of
Threshold Pharmaceuticals

Completed

Study of Hypoxia-Activated Prodrug TH-302 to Treat Advanced Leukemias

Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia | High-risk Myelodysplastic Syndrome | Advanced Myelofibrosis

United States
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating MAC-321 in Non-small Cell Lung Cancer Refractory to Platinum-based Therapy

Carcinoma, Non-Small-Cell Lung | Lung Neoplasms

United States
Sorrento Therapeutics, Inc.

Withdrawn

Study of STI-3031 in Patients With Selected Relapsed or Refractory Solid Tumors

Solid Tumor | Relapsed Solid Tumor | Refractory Tumor
McMaster University
Canadian Institutes of Health Research (CIHR)

Recruiting

Relative Impacts on Preventative Primary Care--a Longitudinal Evaluation of COVID-19:Phase 1 (RIPPLE-C)

Diabetes Mellitus | Chronic Kidney Diseases | Chronic Obstructive Pulmonary Disease | Osteoarthritis | Dementia | Congestive Heart Failure | Depression, Anxiety

Canada
Benitec Biopharma, Inc.

Recruiting

A Study to Evaluate the Safety and Clinical Activity of Intramuscular Doses of BB-301 Administered to Subjects With Oculopharyngeal Muscular Dystrophy With Dysphagia

Oculopharyngeal Muscular Dystrophy

United States
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of BI 34021 FU2 Oral Drinking Solution in Healthy Male Volunteers

Healthy
Sensei Biotherapeutics, Inc.

Withdrawn

SNS-301 Monotherapy in High Risk MDS and CMML

Myelodysplastic Syndromes | Chronic Myelomonocytic Leukemia (CMML)
Celldex Therapeutics

Completed

A Study to Evaluate CDX-301 (rhuFlt3L) in Healthy Volunteers

Healthy

United States
Parion Sciences

Terminated

Evaluation of P-321 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye Disease

Dry Eye Disease

United States
Parion Sciences

Completed

Study of the Safety and Tolerability of P 321 Ophthalmic Solution in Subjects With Dry Eye Disease

Dry Eye Disease

United States
Myeloid Therapeutics

Recruiting

Study of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors (MYE Symphony)

Epithelial Tumors, Malignant

Australia
ContraFect

Completed

A Placebo-Controlled, Dose-Escalating Study to Examine the Safety and Tolerability of Single Intravenous Doses of CF-301 in Healthy Subjects

Staphylococcus Aureus Bloodstream Infections (BSI; Bacteremia)

United States
Evolva SA

Terminated

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of EV-077 in Type 2 Diabetic Subjects

Type 2 Diabetes

Germany
Onconova Therapeutics, Inc.

Recruiting

Study of ON 123300 in Patients With Advanced Cancer

Solid Tumors, Adult

United States
Coordination Pharmaceuticals, Inc.
University of Chicago

Recruiting

Phase I Study of RiMO-301 With Radiation in Advanced Tumors

Advanced Tumors

United States

Search clinical trials for: TOL-3021

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Nigeria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations